Royalty Report: Drugs, Drug Discovery, Therapeutic – Collection: 289216

$100.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 3

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 3

Primary Industries

  • Drugs
  • Drug Discovery
  • Therapeutic

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 289216

License Grant
The Licensor of Japan grants by way of sub-license and license an exclusive right and license under the Patent Rights and the Technical Information & Know-How, to make, have made, offer to provide and provide, develop, manufacture, use, market, sell, offer to sell, and otherwise commercialize the Product in the Territory.
License Property
Licensor has certain rights to an ophthalmic pharmaceutical product containing an active chemical ingredient, defined in detail as the Compound, in any and all delivery forms and presentations, other than transdermal, oral, or parenteral dosage forms.

Compound shall mean the chemical having the structure of (±)-(S)-4-{4-[(4-Chlorophenyl)(2-pyridyl)methoxy]piperidino}butyric acid monobenzenesulfonate, also known as bepotastine besilate and TAU-284 and any enantiomers, salt forms and any other alternate or derivative forms of the chemical compound.

'Product' shall mean any ophthalmic pharmaceutical preparation containing the Compound as an active pharmaceutical ingredient (API), whether alone or in combination with other API s, for use in the treatment of allergies ;md related symptoms, in any and all delivery forms and presentations, other than transdermal, oral, or parenteral dosage forms.

The patents relate to Piperdine and Piperazine Derivatives.

Field of Use
The field of use is on humans in the treatment of allergies and related symptoms.

IPSCIO Record ID: 367335

License Grant
Licensor of Japan grants by way of sub-license and license to Licensee, an exclusive license under the Patent Rights and the Technical Information & Know-How, to develop, manufacture, have manufactured, use, offer to sell, sell, import and otherwise commercialize any and all Products in the Territory.
License Property
Licensor is an exclusive licensee, in certain countries or areas of the world, including the U.S.A., Canada and Mexico, of certain rights to pharmaceutical products containing the Compound in nasal, including intranasal, dosage forms.

Licensor is the owner or the exclusive licensee under an Agreement of certain rights, information and materials related to the Compound and/or the Product and its respective uses and commercialization in certain territory.

Compound shall mean the chemical having the structure of (+)-(S)-4-{4-[(4-Chlorophenyl)(2-pyridyl)methoxy ]piperidino} butyric acid monobenzenesulfonate (also known as bepotastine hesitate and TAU-284) and any Alternate Compounds.

Product shall mean any pharmaceutical product, in any nasal,including but not limited to intranasal, dosage forms, including any applicable delivery devices, containing the Compound as an API.

Licensor Trademark shall mean any trademark selected by the JSC, owned and/or controlled by Licensor to be registered by Licensor in the Territory for the exclusive use by Licensee in the Territory in the commercialization of the Product.

Bepotastine is an investigational product for the treatment of allergy symptoms.

Field of Use
The Field shall mean any and all pharmaceutical products in nasal, including but not limited to intranasal, dosage forms for use in the prevention or treatment of allergic rhinitis and nonallergic rhinitis, and related symptoms, in humans.
Allergic rhinitis is inflammation of the inside of the nose caused by an allergen, such as pollen, dust, mould or flakes of skin from certain animals.

IPSCIO Record ID: 239019

License Grant
The Japanese Licensor grants a sole and exclusive license under the Patent Rights and the Technical Information and Know-How to manufacture or have manufactured the Compound in or outside of the Territory for production of Product to be sold in the Territory, to make the Product and have the Product made by a Third Party or Affiliate as described in this Article, and, to develop, use, promote, market, offer to sell, sell and otherwise commercialize the Product in the Territory.

The Licensee intends to develop, manufacture, use, obtain governmental approval for, offer to sell, sell, and commercialize the Product in certain countries or areas of North America.

License Property
The patents and know-how are for Drugs for ameliorating ocular circulatory disorders;   1 ,4-dihydropyridine derivatives and pharmaceutical composition thereof;   Anti-inflammatory agents and inhibitors against increase in ocular tension caused by irradiation with lasers, containing 1,4- dihydropyridine derivatives; and,  Inhibitor of visual function disturbance caused by optic nerve cell disorder due to factor other than ophthalmic circulatory disorder.

Compound shall mean the substance 3- (4-Allyl-1-piperazinyl)-2, 2-dimethylpropylmethyl 1,4-dihydro-2, 6-dimethyl-4-(3-nitrophenyl)-3, 5-pyridine dicarboxylate dihydrochloride, (also known as iganidipine dihydrochloride and KS-288), including without limitation, all enantiomers and any other alternate or derivative forms.

Product shall mean any ophthalmic pharmaceutical product containing the Compound as an active pharmaceutical ingredient (API), whether alone or in combination with other API s, in any and all delivery forms and presentations other than transdermal, oral, or parenteral dosage forms.

Field of Use
The product is for use in the ophthalmic field.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.